| Name | Title | Contact Details |
|---|
RotaChrom Technologies is the inventor and first worldwide manufacturer of the Industrial Scale Centrifugal Partition Chromatography (iCPC) platforms. The company revolutionizes the pharmaceutical and cannabis industries by manufacturing and selling unique inventions of a special purifying technology. A cost-efficient and easily adaptable separation solution is offered for active pharmaceutical ingredients (API) and cannabinoids. The cost and the risk profile of R&D, as well as production can be significantly lower by using CPC tools, thereby pharmaceutical and cannabis-based products can become more widely available. Since its establishment, the company has achieved massive international success in pharmaceutical and pharma-graded cannabis purification. It has become an industry-leading company by setting global purification standards in the cannabis industry. RotaChrom’s CPC platforms are quintessential applications when looking for a high-purity and high-capacity, yield-focused solution.
MBC Pharma (Main) is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ryan TrueHealth is a Wilton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.
We are a community of approximately 825 women religious. Originally founded in 1650 in LePuy, France, the Sisters of Saint Joseph came to Philadelphia in 1847. Through our many ministries, including educations, healthcare, social services and parish m...